Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Eur J Radiol. 2021 Jan 9;136:109534. doi: 10.1016/j.ejrad.2021.109534

Figure 3.

Figure 3.

A) Over the course of NAT, the rate of fibroglandular tissue enhancement declined in 17 of 19 patients. B) When normalized to the rate of enhancement prior to therapy, the relative rate of fibroglandular enhancement declined over the treatment period (p < 0.05). C) The relative enhancement of fibroglandular tissue also declined longitudinally over NAT in 17 of 19 patients. D) When normalized to the intensity of enhancement prior to therapy, the relative fibroglandular enhancement trended toward a decline over the treatment period, but did not reach statistical significance (p < 0.05).